GSK struck a pact worth up to $357 million with French biotech Syndivia for a preclinical prostate cancer antibody-drug conjugate (ADC). The agreement, disclosed after a European cancer conference focused on ADCs, gives GSK access to a Syndivia program and positions the pharma to expand its oncology ADC pipeline. The deal highlights Big Pharma’s continued appetite for early ADC assets and reflects investor interest in partnering to de-risk preclinical oncology candidates.